Note 5 - Fair Value Measurements (Details Textual) $ / shares in Units, $ in Thousands		1 Months Ended
	Jan. 07, 2024 USD ($) $ / shares shares	Mar. 31, 2010 USD ($) $ / shares
Manhattan and Ariston Pharmaceuticals Merger [Member]
Notes Issued		$ 15,500
Debt Instrument, Term (Year)		5 years
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 1,125
Precision BioSciences, Inc. [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares) | shares	2,920,816
Investment Purchased Balance Price Per Share (in dollars per share) | $ / shares	$ 0.77
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront	$ 7,500
License Agreement, Amount Paid Upfront, Cash	5,250
License Agreement, Amount Paid Upfront, Equity Investment	2,250
License Agreement, Deferred Payment	$ 2,500
License Agreement, Payment, Percentage of Weighted Average Share Price	200.00%
License Agreement, Share Price, Trading Days (Day)	30 days
License Agreement, Milestone Stock Payment	$ 2,300